SUBSCRIBERS

In global race for cancer therapy, a Chinese biotech firm surges

Published Wed, Feb 14, 2018 · 09:50 PM

Beijing

IN THE global race to use human immune cells to fight cancers, a little-known Chinese firm called GenScript Biotech Corp is emerging as one of the biggest stock gainers.

Among the first Chinese developers of so-called CAR-T cancer therapies, GenScript's shares have risen more than sixfold since June, when it reported positive results from early studies in 35 patients with a type of blood cancer.

Now the company expects the go- ahead from Chinese regulators to start formal human trials as early as the second quarter. The drug cou…

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes

Consumer & Healthcare

Lululemon to shutter Washington distribution center, lay off 128 employees
Gazelle Ventures makes cash offer for No Signboard shares at S$0.0021 apiece
P&G raises annual core profit forecast on resilient demand, price hikes
Cordlife calls for trading halt after shares sink to all-time low, pending announcement
Marina Bay Sands Q1 profit surges 51.5% to US$597 million on tourism boom
Swiss watch exports plunge as China and Hong Kong demand dries up

Companies & Markets

In global race for cancer therapy, a Chinese biotech firm surges

Consumer & Healthcare

Lululemon to shutter Washington distribution center, lay off 128 employees

Gazelle Ventures makes cash offer for No Signboard shares at S$0.0021 apiece

P&G raises annual core profit forecast on resilient demand, price hikes

Cordlife calls for trading halt after shares sink to all-time low, pending announcement

Marina Bay Sands Q1 profit surges 51.5% to US$597 million on tourism boom

Swiss watch exports plunge as China and Hong Kong demand dries up

SUPPORT SOUTH-EAST ASIA'S LEADING FINANCIAL DAILY

SECTIONS

LIFESTYLE

Follow BT